Kisho

Intercept Pharmaceuticals, Inc. — Rare Disease Pipeline | Kisho | Kisho

Intercept Pharmaceuticals, Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
primary biliary cholangitis	Obeticholic Acid; BezafibrateOCALIVA	Orphan Designation	-
primary biliary cholangitis 1	OCALIVA	Orphan Designation	-
primary biliary cholangitis 2	OCALIVA	Orphan Designation	-
primary biliary cholangitis 4	OCALIVA	Orphan Designation	-
primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome	OCALIVA	Orphan Designation	-
primary sclerosing cholangitis	6-alpha-ethylchenodeoxycholic acid	Orphan Designation	-